This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Accumulating evidence indicates a frequent association between CAP and acute cardiac complications, including atrial fibrillation, HF and myocardial infarction.1 Multiple clinical studies have reported a 2- to eightfold increase in CVD risk within first 30 days after respiratory infections.2 CV complications develop in up to 30% of patients hospitalised for CAP, even up to 10 years thereafter.3 Among patients with pneumonia, acute myocardial infarction or unstable angina is reported in 5% of cases, new-onset arrhythmias in 12% cases and chronic heart failure in 14% cases. Studies have identified several risk factors for CV events in patients with CAP, such as older age, pre-existing CV or chronic respiratory conditions, hospital-stay, older age, severity of CAP and smoking.4
A matched cohort study investigated whether hospitalisation due to pneumonia was associated with increased risk of CVD. The study reported that pneumonia-related hospitalisation is associated with increased short-term (up to 1 year) and long-term (10 years) CVD risk, thereby indicating that pneumonia is a risk factor for CVD.2 Another multicentre study prospectively followed 1182 hospitalised patients with CAP for up to 30 days for CV events. The study reported intrahospital CV events in 32.2% of patients with CAP, while 2.4% patients died because of CV causes. The study revealed that CV events occur in around one-third of patients hospitalised for CAP, and such events are associated with a fivefold increase in CAP-associated mortality within 30 days.1
A recent retrospective observational study reported that patients with CVD are at higher risk of both CAP and HAP, and have higher frequency of ICU admissions. Additionally, regardless of comorbidities, age, gender and antibiotic use, pneumonia risk was particularly associated with HF, especially in elderly male patients.5
Another recent systematic review and meta-analysis of 39 studies involving 92,188 patients revealed that overall cardiac complications occurred in 13.9% of CAP cases. Heart failure was observed in 7.2% of pooled patients, while acute coronary syndromes, arrhythmias and stroke occurred in 4.5%, 7.2% and 0.71% of patients with CAP, respectively.6
CAP, community-acquired pneumonia; CV, cardiovascular; CVD, cardiovascular disease; HAP, hospital-acquired pneumonia; HF, heart failure; ICU, intensive coronary unit.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.